KR102533875B1 - 항-cd19 항체 제제 - Google Patents

항-cd19 항체 제제 Download PDF

Info

Publication number
KR102533875B1
KR102533875B1 KR1020197002043A KR20197002043A KR102533875B1 KR 102533875 B1 KR102533875 B1 KR 102533875B1 KR 1020197002043 A KR1020197002043 A KR 1020197002043A KR 20197002043 A KR20197002043 A KR 20197002043A KR 102533875 B1 KR102533875 B1 KR 102533875B1
Authority
KR
South Korea
Prior art keywords
concentration
liquid formulation
antibody
formulation
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197002043A
Other languages
English (en)
Korean (ko)
Other versions
KR20190021373A (ko
Inventor
패트릭 가리델
안드레아스 란게르
마틴 헤슬링
다니엘 바인퍼트너
보도 브록스
Original Assignee
모르포시스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모르포시스 아게 filed Critical 모르포시스 아게
Priority to KR1020237016157A priority Critical patent/KR20230074823A/ko
Publication of KR20190021373A publication Critical patent/KR20190021373A/ko
Application granted granted Critical
Publication of KR102533875B1 publication Critical patent/KR102533875B1/ko
Assigned to 인사이트 코포레이션 reassignment 인사이트 코포레이션 권리의 전부이전등록 Assignors: 모르포시스 아게
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020197002043A 2016-06-27 2017-06-27 항-cd19 항체 제제 Active KR102533875B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237016157A KR20230074823A (ko) 2016-06-27 2017-06-27 항-cd19 항체 제제

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16176322.2 2016-06-27
EP16176322 2016-06-27
PCT/EP2017/065819 WO2018002031A1 (en) 2016-06-27 2017-06-27 Anti-cd19 antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237016157A Division KR20230074823A (ko) 2016-06-27 2017-06-27 항-cd19 항체 제제

Publications (2)

Publication Number Publication Date
KR20190021373A KR20190021373A (ko) 2019-03-05
KR102533875B1 true KR102533875B1 (ko) 2023-05-18

Family

ID=56368805

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197002043A Active KR102533875B1 (ko) 2016-06-27 2017-06-27 항-cd19 항체 제제
KR1020237016157A Ceased KR20230074823A (ko) 2016-06-27 2017-06-27 항-cd19 항체 제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237016157A Ceased KR20230074823A (ko) 2016-06-27 2017-06-27 항-cd19 항체 제제

Country Status (26)

Country Link
US (2) US11352423B2 (https=)
EP (2) EP3475303B1 (https=)
JP (3) JP2019524671A (https=)
KR (2) KR102533875B1 (https=)
CN (2) CN109415440B (https=)
AU (2) AU2017289085B2 (https=)
CA (1) CA3029137A1 (https=)
CY (1) CY1124521T1 (https=)
DK (1) DK3475303T3 (https=)
ES (1) ES2874640T3 (https=)
HR (1) HRP20210945T1 (https=)
HU (1) HUE054296T2 (https=)
IL (1) IL263764B2 (https=)
LT (1) LT3475303T (https=)
MA (1) MA45450B1 (https=)
MD (1) MD3475303T2 (https=)
MX (1) MX2018016362A (https=)
PL (1) PL3475303T3 (https=)
PT (1) PT3475303T (https=)
RS (1) RS62035B1 (https=)
RU (1) RU2748024C2 (https=)
SG (2) SG10201912369QA (https=)
SI (1) SI3475303T1 (https=)
SM (1) SMT202100317T1 (https=)
WO (1) WO2018002031A1 (https=)
ZA (1) ZA201900483B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100541T1 (it) 2015-08-21 2021-11-12 Morphosys Ag Combinazioni e loro usi
IL301786B2 (en) 2016-10-28 2025-09-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
US12544437B2 (en) 2019-10-04 2026-02-10 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant AAV
US20210130461A1 (en) 2019-10-31 2021-05-06 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
US20230014026A1 (en) 2020-06-22 2023-01-19 Morphosys Ag Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
JP2023545099A (ja) 2020-10-08 2023-10-26 アフィメド ゲーエムベーハー 三重特異性バインダー
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
AU2022382368A1 (en) 2021-11-03 2024-05-02 Affimed Gmbh Bispecific cd16a binders
IL316747A (en) * 2022-05-03 2025-01-01 Xencor Inc Lymphoma treatment methods
IL318787A (en) 2022-08-17 2025-04-01 Incyte Corp Treatment including ANTI-CD19 antibodies and EZH2 modulators
IL322510A (en) * 2023-03-02 2025-10-01 Novetide Ltd Method for preparing GLP-1 peptides with controlled particle size
CN120754244B (zh) * 2025-09-10 2025-12-12 江苏豪森药业集团有限公司 一种含抗cd19抗体的药物组合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015001504A2 (en) * 2013-07-04 2015-01-08 Neotope Biosciences Limited Antibody formulations and methods
WO2015157286A1 (en) * 2014-04-07 2015-10-15 Seattle Genetics, Inc. Stable formulations for anti-cd19 antibodies and antibody-drug conjugates

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
PL2383297T3 (pl) * 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
RU2476441C2 (ru) 2007-10-19 2013-02-27 Сиэтл Дженетикс, Инк. Cd19-связывающие средства и их применение
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
EP2398829A2 (en) 2009-02-23 2011-12-28 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
MX2011009312A (es) * 2009-03-06 2012-02-29 Medimmune Llc Formulaciones de anticuerpos humanizados anti-cd19.
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
CN110538322A (zh) 2013-03-13 2019-12-06 豪夫迈·罗氏有限公司 抗体配制剂
IL269947B (en) 2013-03-13 2022-08-01 Genentech Inc Formulations with reduced oxidation
MX375378B (es) 2013-09-27 2025-03-06 Genentech Inc Formulaciones de anticuerpos anti-pdl1.
KR102372245B1 (ko) * 2013-11-21 2022-03-08 젠맵 에이/에스 항체-약물 접합체 동결건조 제제

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015001504A2 (en) * 2013-07-04 2015-01-08 Neotope Biosciences Limited Antibody formulations and methods
WO2015157286A1 (en) * 2014-04-07 2015-10-15 Seattle Genetics, Inc. Stable formulations for anti-cd19 antibodies and antibody-drug conjugates

Also Published As

Publication number Publication date
DK3475303T3 (da) 2021-05-31
KR20190021373A (ko) 2019-03-05
EP3475303A1 (en) 2019-05-01
RU2019100221A (ru) 2020-07-28
LT3475303T (lt) 2021-06-25
CY1124521T1 (el) 2022-07-22
NZ748681A (en) 2025-06-27
MX2018016362A (es) 2019-04-22
ZA201900483B (en) 2021-06-30
EP3475303B1 (en) 2021-04-14
ES2874640T3 (es) 2021-11-05
AU2017289085A1 (en) 2018-12-13
RS62035B1 (sr) 2021-07-30
PT3475303T (pt) 2021-06-25
MA45450B1 (fr) 2021-04-30
CA3029137A1 (en) 2018-01-04
JP2024109816A (ja) 2024-08-14
JP2019524671A (ja) 2019-09-05
RU2748024C2 (ru) 2021-05-19
WO2018002031A1 (en) 2018-01-04
MD3475303T2 (ro) 2021-09-30
IL263764A (en) 2019-01-31
EP3909985A1 (en) 2021-11-17
US11352423B2 (en) 2022-06-07
CN109415440A (zh) 2019-03-01
PL3475303T3 (pl) 2021-12-06
JP7603201B2 (ja) 2024-12-20
RU2019100221A3 (https=) 2020-11-30
HUE054296T2 (hu) 2021-08-30
IL263764B2 (en) 2024-09-01
JP2022119854A (ja) 2022-08-17
AU2024205042A1 (en) 2024-08-15
CN109415440B (zh) 2022-12-06
AU2017289085B2 (en) 2024-07-18
HRP20210945T1 (hr) 2021-09-17
US20190322742A1 (en) 2019-10-24
SG11201810429UA (en) 2018-12-28
SI3475303T1 (sl) 2021-12-31
CN115998859A (zh) 2023-04-25
KR20230074823A (ko) 2023-05-31
US20220213190A1 (en) 2022-07-07
IL263764B1 (en) 2024-05-01
JP7824990B2 (ja) 2026-03-05
SMT202100317T1 (it) 2021-07-12
SG10201912369QA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
JP7824990B2 (ja) 抗ｃｄ１９抗体製剤
CN110732023A (zh) 一种her2抗体药物组合物及其用途
CA3064470A1 (en) Pharmaceutical composition comprising c-met antibody-drug conjugate and use thereof
CA3105360A1 (en) Combination therapy with targeted tgf-b inhibition for treatment of advanced non-small cell lung cancer
CA3096844A1 (en) Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects
CN112839961B (zh) 一种cd40抗体药物组合物及其用途
HK40064043A (en) Anti-cd19 antibody formulations
RU2848327C1 (ru) Составы на основе антитела к CD19
HK40004579B (en) Anti-cd19 antibody formulations
HK40004579A (en) Anti-cd19 antibody formulations
HK40004117B (zh) 抗-cd19抗体制剂
NZ789731A (en) Anti-CD19 antibody formulations
HK40004117A (en) Anti-cd19 antibody formulations
TW202417512A (zh) 含有抗tigit抗體的配製物及其使用方法
CA3250813A1 (en) PHARMACEUTICAL FORMULATIONS OF AN ANTI-ILT4 ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT OF IT AND METHODS OF USE

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200625

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220512

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230215

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230515

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230516

End annual number: 3

Start annual number: 1

PG1601 Publication of registration